(Q34409185)

2 August 2017

title

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial (English)

1 reference

2 August 2017

main subject

Clostridium difficile

0 references

author name string

P Patrick Basu

1

1 reference

2 August 2017

Amreen Dinani

2

1 reference

2 August 2017

Krishna Rayapudi

3

1 reference

2 August 2017

Tommy Pacana

4

1 reference

2 August 2017

Niraj James Shah

5

1 reference

2 August 2017

Hemant Hampole

6

1 reference

2 August 2017

N V Krishnaswamy

7

1 reference

2 August 2017

Vinod Mohan

8

1 reference

2 August 2017

publication date

1 July 2010

1 reference

Therapeutic Advances in Gastroenterology

2 August 2017

published in

1 reference

2 August 2017

volume

3

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

221-225

1 reference

Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

Implications of the changing face of Clostridium difficile disease for health care practitioners

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

Clostridium difficile--Associated diarrhea: A review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002581

In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10372985

Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10372985

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10372985

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X10372985

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21180604

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High dosage rifaximin for the treatment of small intestinal bacterial overgrowth

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21180604

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21180604

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1756283X10372985

1 reference

2 August 2017

1 reference

2 August 2017

1 reference